147 related articles for article (PubMed ID: 36882122)
81. In vitro synthesis of mucin-type O-glycans using saccharide primers comprising GalNAc-Ser and GalNAc-Thr residues.
Sakura R; Nagai K; Yagi Y; Takahashi Y; Ide Y; Yagi Y; Yamamoto D; Mizuno M; Sato T
Carbohydr Res; 2022 Jan; 511():108495. PubMed ID: 35026558
[TBL] [Abstract][Full Text] [Related]
82. Distribution of oncofetal fibronectin isoforms in normal, hyperplastic and neoplastic human breast tissues.
Kaczmarek J; Castellani P; Nicolo G; Spina B; Allemanni G; Zardi L
Int J Cancer; 1994 Oct; 59(1):11-6. PubMed ID: 7927891
[TBL] [Abstract][Full Text] [Related]
83. Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway.
Chen T; Wang C; Liu Q; Meng Q; Sun H; Huo X; Sun P; Peng J; Liu Z; Yang X; Liu K
Cancer Biol Ther; 2015; 16(1):106-14. PubMed ID: 25482933
[TBL] [Abstract][Full Text] [Related]
84. C-phycocyanin to overcome the multidrug resistance phenotype in human erythroleukemias with or without interaction with ABC transporters.
Fernandes E Silva E; Figueira FS; Cañedo AD; Machado KS; Salgado MTSF; Silva TK; Wagner EF; Mattozo FH; Lima ÉA; Sales-Neto JM; Ferreira VU; Comitre AA; Mascarenhas SR; Kalil SJ; Votto APS
Biomed Pharmacother; 2018 Oct; 106():532-542. PubMed ID: 29990841
[TBL] [Abstract][Full Text] [Related]
85. Co-expression of cytokeratin 8 and breast cancer resistant protein indicates a multifactorial drug-resistant phenotype in human breast cancer cell line.
Liu F; Fan D; Qi J; Zhu H; Zhou Y; Yang C; Zhu Z; Xiong D
Life Sci; 2008 Sep; 83(13-14):496-501. PubMed ID: 18725232
[TBL] [Abstract][Full Text] [Related]
86. Molecular cloning and characterization of a novel member of the UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase family, pp-GalNAc-T12.
Guo JM; Zhang Y; Cheng L; Iwasaki H; Wang H; Kubota T; Tachibana K; Narimatsu H
FEBS Lett; 2002 Jul; 524(1-3):211-8. PubMed ID: 12135769
[TBL] [Abstract][Full Text] [Related]
87. Co-suppression of MDR1 (multidrug resistance 1) and GCS (glucosylceramide synthase) restores sensitivity to multidrug resistance breast cancer cells by RNA interference (RNAi).
Zhang X; Li J; Qiu Z; Gao P; Wu X; Zhou G
Cancer Biol Ther; 2009 Jun; 8(12):1117-21. PubMed ID: 19502811
[TBL] [Abstract][Full Text] [Related]
88. Unexpected tolerance of glycosylation by UDP-GalNAc:polypeptide alpha-N-acetylgalactosaminyltransferase revealed by electron capture dissociation mass spectrometry: carbohydrate as potential protective groups.
Yoshimura Y; Matsushita T; Fujitani N; Takegawa Y; Fujihira H; Naruchi K; Gao XD; Manri N; Sakamoto T; Kato K; Hinou H; Nishimura S
Biochemistry; 2010 Jul; 49(28):5929-41. PubMed ID: 20540529
[TBL] [Abstract][Full Text] [Related]
89. Impact of BCRP/MXR, MRP1 and MDR1/P-Glycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cells.
Stein U; Lage H; Jordan A; Walther W; Bates SE; Litman T; Hohenberger P; Dietel M
Int J Cancer; 2002 Feb; 97(6):751-60. PubMed ID: 11857350
[TBL] [Abstract][Full Text] [Related]
90. Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters.
Mi YJ; Liang YJ; Huang HB; Zhao HY; Wu CP; Wang F; Tao LY; Zhang CZ; Dai CL; Tiwari AK; Ma XX; To KK; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2010 Oct; 70(20):7981-91. PubMed ID: 20876799
[TBL] [Abstract][Full Text] [Related]
91. Polypeptide N-acetylgalactosaminyltransferase 6 disrupts mammary acinar morphogenesis through O-glycosylation of fibronectin.
Park JH; Katagiri T; Chung S; Kijima K; Nakamura Y
Neoplasia; 2011 Apr; 13(4):320-6. PubMed ID: 21472136
[TBL] [Abstract][Full Text] [Related]
92. Inhibition of protein glycosylation reverses the MDR phenotype of cancer cell lines.
Wojtowicz K; Januchowski R; Nowicki M; Zabel M
Biomed Pharmacother; 2015 Aug; 74():49-56. PubMed ID: 26349962
[TBL] [Abstract][Full Text] [Related]
93. Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes.
Calcagno AM; Fostel JM; To KK; Salcido CD; Martin SE; Chewning KJ; Wu CP; Varticovski L; Bates SE; Caplen NJ; Ambudkar SV
Br J Cancer; 2008 May; 98(9):1515-24. PubMed ID: 18382425
[TBL] [Abstract][Full Text] [Related]
94. Expression of polypeptide GalNAc-transferases in stratified epithelia and squamous cell carcinomas: immunohistological evaluation using monoclonal antibodies to three members of the GalNAc-transferase family.
Mandel U; Hassan H; Therkildsen MH; Rygaard J; Jakobsen MH; Juhl BR; Dabelsteen E; Clausen H
Glycobiology; 1999 Jan; 9(1):43-52. PubMed ID: 9884405
[TBL] [Abstract][Full Text] [Related]
95. The lectin domain of UDP-N-acetyl-D-galactosamine: polypeptide N-acetylgalactosaminyltransferase-T4 directs its glycopeptide specificities.
Hassan H; Reis CA; Bennett EP; Mirgorodskaya E; Roepstorff P; Hollingsworth MA; Burchell J; Taylor-Papadimitriou J; Clausen H
J Biol Chem; 2000 Dec; 275(49):38197-205. PubMed ID: 10984485
[TBL] [Abstract][Full Text] [Related]
96. Reversal of P-glycoprotein-mediated multidrug resistance is induced by saikosaponin D in breast cancer MCF-7/adriamycin cells.
Li C; Guan X; Xue H; Wang P; Wang M; Gai X
Pathol Res Pract; 2017 Jul; 213(7):848-853. PubMed ID: 28554760
[TBL] [Abstract][Full Text] [Related]
97. Mucin-type O-glycosylation in helminth parasites from major taxonomic groups: evidence for widespread distribution of the Tn antigen (GalNAc-Ser/Thr) and identification of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase activity.
Casaravilla C; Freire T; Malgor R; Medeiros A; Osinaga E; Carmona C
J Parasitol; 2003 Aug; 89(4):709-14. PubMed ID: 14533679
[TBL] [Abstract][Full Text] [Related]
98. Immunosuppressors and reversion of multidrug-resistance.
Aouali N; Eddabra L; Macadré J; Morjani H
Crit Rev Oncol Hematol; 2005 Oct; 56(1):61-70. PubMed ID: 15978826
[TBL] [Abstract][Full Text] [Related]
99. Studies on the order and site specificity of GalNAc transfer to MUC1 tandem repeats by UDP-GalNAc: polypeptide N-acetylgalactosaminyltransferase from milk or mammary carcinoma cells.
Stadie TR; Chai W; Lawson AM; Byfield PG; Hanisch FG
Eur J Biochem; 1995 Apr; 229(1):140-7. PubMed ID: 7744025
[TBL] [Abstract][Full Text] [Related]
100. Characterization of a UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase that displays glycopeptide N-acetylgalactosaminyltransferase activity.
Ten Hagen KG; Tetaert D; Hagen FK; Richet C; Beres TM; Gagnon J; Balys MM; VanWuyckhuyse B; Bedi GS; Degand P; Tabak LA
J Biol Chem; 1999 Sep; 274(39):27867-74. PubMed ID: 10488133
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
